Multisession Cyberknife radiosurgery for post-surgical residual and recurrent pituitary adenoma: preliminary result from one center
Yuan-Hao Chen, Steven D. Chang, Hsin-I Ma, Yu-Ching Chou, Hsing-Lung Chao, Yee-Min Jen and Da-Tong Ju
Objective: To evaluate the efficacy of CyberKnife (Accuray, Inc., Sunnyvale, CA) stereotactic radiosurgery (SRS) for patients with pituitary adenoma.
Materials and Methods: We conducted a retrospective review of all patients treated by image-guided radiosurgery at our institution between August 2007 and June 2009. Twenty-two patients with pituitary adenoma were identified. The median follow-up period from date of treatment was 30.8 + 7.7months. The median patient age was 56 years. The mean tumor volume was 4.1 + 2.8 mL (range, 0.8- 16.0 mL), and the prescribed dose was 25 Gy (5 Gy x 5).
Results: Tumors were treated with a mean coverage of 95.1 ± 1.3% (range 90.2-99.1%), a mean conformality index of 1.4 ± 0.4 (range, 1.2-1.8), and a mean treatment isodose line of 76.4 ± 3.0%(range70-83%). The primary endpoints were radiographic and endocrinological tumor control. The local radiographic control rate in this series was 100% (22/22). Radiographic evidence of tumor necrosis developed in 3 patients (13.7%).
Conclusions: CyberKnife multisession radiosurgery of 25 Gy (5 Gy x 5) provided excellent local control with acceptable adverse effect in patients with pituitary adenoma post-transsphenoidal resection. This preliminary study provides data that supports the belief that the optic nerve and chiasm tolerate the above dosing regimens in perichiasmatic pituitary adenomas, and this dosing regimen may achieve satisfactory radiographic and endocrinological tumor control for post-transsphenoidal resection.
Keywords: CyberKnife, Radiosurgery and Pituitary Adenoma
Full Text (IP)
Purchase Article (PDF)